Results 21 to 30 of about 1,454 (181)

New Gepants Against Acute Migraine A Systematic Review and Network Meta-Analysis

Amrita Journal of Medicine, 2021
Objectives: Recently two calcitonin gene-related peptide receptor antagonists (ubrogepant and rimegepant) were approved for the acute attack of migraine.
Dhyuti Gupta, Suryaprakash Dhaneria, Alok Singh   +2 more
doaj   +2 more sources

Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics

The Journal of Headache and Pain
Background Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, but it is not ...
Deirdre M. Boucherie, Ruben Dammers, Arnaud Vincent, A. H. Jan Danser, Antoinette MaassenVanDenBrink   +4 more
doaj   +3 more sources

Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations

Cephalalgia Reports
Background: Small molecule receptor antagonists (gepants), or monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) have recently become available for migraine prophylaxis and/or acute treatment.
Andrea Burgalassi, Giulia Vigani, Alberto Boccalini, Francesco De Cesaris, Guido Mannaioni, Alberto Chiarugi, Pierangelo Geppetti, Luigi Francesco Iannone   +7 more
doaj   +2 more sources

Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review. [PDF]

Headache
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Hyland AC, Belfer SJ, Fox CK, Irwin SL, Vassar R, Oh A, Ilangovan S, Gelfand AA.   +7 more
europepmc   +2 more sources

Gepants in Migraine Treatment: Cardiovascular Safety and Clinical Implications

Quality in Sport
Migraine is a prevalent chronic neurological disorder associated with significant disability and an increased risk of cardiovascular diseases, particularly ischemic stroke and myocardial infarction. Calcitonin gene-related peptide (CGRP), a key mediator of migraine pathophysiology, plays an important role in pain transmission and vascular regulation ...
Katarzyna Solecka, Karolina Fengler, Agata Urbanik, Olga Jakubowska, Dominika Kominiak, Zuzanna Oćwieja, Agata Wyborska, Kamila Weronika Pietrzak, Mikołaj Mińkowski, Marcel Gascon Carreno   +9 more
core   +3 more sources

Combining treatments for migraine prophylaxis: the state-of-the-art [PDF]

The Journal of Headache and Pain
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A ...
Lanfranco Pellesi, David Garcia-Azorin, Eloisa Rubio-Beltrán, Wook-Seok Ha, Roberta Messina, Raffaele Ornello, Igor Petrusic, Bianca Raffaelli, Alejandro Labastida-Ramirez, Ruth Ruscheweyh, Claudio Tana, Doga Vuralli, Marta Waliszewska-Prosół, Wei Wang, William Wells-Gatnik   +14 more
doaj   +2 more sources

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab

Pharmaceuticals, 2021
Migraine is the second cause of disability and of lost years of healthy life worldwide. Migraine is characterized by recurrent headache attacks and accompanying disabling symptoms lasting 4–48 h.
Damiana Scuteri, Giacinto Bagetta
doaj   +1 more source

Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]

Headache
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments.
Lipton RB, Dodick DW, Davis L, Nahas SJ, Goadsby PJ.   +4 more
europepmc   +3 more sources

Blocking the CGRP Receptor: Differences across Human Vascular Beds

Pharmaceuticals, 2023
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM–1 µM) on CGRP-induced relaxation in ...
Tessa de Vries, Deirdre M. Boucherie, Antoon van den Bogaerdt, A. H. Jan Danser, Antoinette MaassenVanDenBrink   +4 more
doaj   +1 more source

A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine

, 2022
Gepants are small molecules targeting the calcitonin gene-related peptide (CGRP) that have been recently introduced and are under additional clinical development as preventive and abortive treatment options for ...
Mantovani, Elisa, Mitsikostas, Dimos-Dimitrios, Tamburin, Stefano, Vikelis, Michail, Argyriou, Andreas A, Elisa Mantovani, Dimos-Dimitrios Mitsikostas, Stefano Tamburin, Andreas A. Argyriou, Michail Vikelis   +9 more
core   +2 more sources